Lessons from the Helsinki Heart Study

Preview

Abnormal lipid and lipoprotein patterns pose a serious threat to cardiovascular health. Often, normalization cannot be achieved without pharmacologic intervention. One class of drugs that shows promise in altering lipid levels is the fibric acids. In this article, Dr Grundy summarizes the results of a five-year trial of the fibric acid gemfibrozil (Lopid). He also discusses the effects on lipid transport and the differences in action of fibric acids as well as the indications for their use.